It is strongly recommended that tissue and synovial fluid culture samples be obtained during reimplantation performed as part of a two-stage exchange arthroplasty. The incidence of positive cultures during reimplantation and the influence of positive cultures on subsequent outcome are unknown. This aim of this study was to determine the incidence of positive cultures during reimplantation and to investigate the association between positive cultures at reimplantation and the subsequent outcome A retrospective review was conducted on 267 patients that met the Musculoskeletal Infection Society (MSIS) criteria for PJI that completed both stages of two-stage exchange arthroplasty (Table 1). Intraoperative culture results from tissue and/or synovial fluid were obtained. Cultures were positive in 33 cases (12.4%) undergoing reimplantation surgery (Figure 1). Treatment failure was assessed based on the Delphi consensus definition. Logistic regression analysis was performed to assess the predictors of positive culture and risk factors for failure of two-stage exchange arthroplasty. Treatment failure was 45.5% for those with a positive intraoperative culture and 20.9% in those with negative cultures at the time of reimplantation. When controlling for organism virulence, comorbidities, and other confounding factors, treatment failure was higher (odds ratio [OR]: 3.3; 95% confidence interval [CI]: 1.3–4.5) and occurred at an earlier time point (hazard ratio: 2.5; 95% CI: 1.3–4.5) in patients with a positive reimplantation culture. The treatment failure rate was not different between cases with two or more positive cultures (36.4%) and one positive culture (42.8%). Positive intraoperative cultures during reimplantation, regardless of the number of positive samples were independently associated with two times the risk of subsequent infection and earlier treatment failure. Surgeons should be aware that a positive culture at the time of reimplantation independently increases the risk of subsequent failure and needs to be taken seriously. Given the significance of these findings, future studies are needed to evaluate the optimal management of positive cultures during reimplantation surgery.
Preoperative antibiotic prophylaxis remains one of the most important strategies for preventing periprosthetic joint infection (PJI). Current guidelines recommend giving universal antibiotic prophylaxis to all total joint arthroplasty (TJA) patients regardless of their medical conditions or immune status. The aims of this study were to determine if comorbidities influence the organism profile of PJIs and to investigate if the efficacy of the two most frequently used perioperative antibiotics (cefazolin or vancomycin) are affected by patient comorbidities. Using an institutional database, the influence of comorbidities on the organism profile of 1022 PJIs was evaluated. To investigate the influence of perioperative antibiotic monotherapy (cefazolin or vancomycin therapy) on PJI, 8575 primary TJAs were identified and analyzed based on their comorbidities. Patients with multiple perioperative antibiotics, prior septic arthritis, unavailable perioperative antibiotic information, or who underwent aseptic revision were excluded. PJI was determined from ICD-9 codes. While no comorbidities were associated with an increased rate of gram-positive or gram-negative infections, metastatic disease (odds ratio [OR] 7.54, p=0.006), rheumatologic disease (OR 1.63, p=0.046), and chronic pulmonary disease (OR 1.46, p=0.030) demonstrated an increased risk of Staphylococcus aureus PJI. In addition, metastatic disease (OR 5.71, 95% confidence interval [CI] 1.12–26.93, p=0.018), congestive heart failure (OR 2.2, 95% CI 1.16–4.00, p=0.010), chronic pulmonary disease (OR 1.76; 95% CI 1.09–2.78, p=0.015), and diabetes (OR 1.66; 95% CI 1.08–2.52, p=0.019) were associated with PJI from antibiotic resistant organisms. However, there was no difference in the rate of PJI between cefazolin and vancomycin monotherapy when stratified for the aforementioned comorbidities. The present study reveals that comorbidities do not significantly alter the organism profile of high-risk comorbidities and that comorbidities associated with immune deficits do not influence the rate of PJI between two different antibiotics. The results of this study thus support current guidelines, which provide a universal recommendation rather than a protocol that is tailored to a patient's preexisting comorbidities.
Failure of a two-stage exchange arthroplasty for management of periprosthetic joint infection (PJI) poses a major clinical challenge. There is a paucity of information regarding the outcome of further surgical intervention in these patients. Thus, we aim to report the clinical outcomes of subsequent surgical intervention following a failed prior two-stage exchange. Our institutional database was used to identify 60 patients (42 knees and 18 hips) with a failed prior two-stage exchange from infection, who underwent further surgical intervention between 1998 and 2012 and had a minimum of two years follow-up. A retrospective review was performed to extract relevant clinical information, such as mortality, microbiology, and subsequent surgeries. Musculoskeletal Infection Society criteria were used to define PJI, and treatment success was defined using the Delphi criteria as previously reported. Irrigation and debridement (I&D) was performed after a failed two-stage exchange in 61.7% (37/60) patients. The failure rate of I&D in this cohort was 51.3% (19/37). Two patients underwent amputation after I&D due to uncontrolled infection. A total of 40 patients underwent an intended a second two-stage exchange. Reimplantation occurred in only 65% of cases (26/40), and infection was controlled in 61.6% (16/26) of patients. An interim spacer exchange was required in 15% (6/40) of the cases. Of the 14 cases that did not undergo a second stage reimplantation, 5 required amputation, 6 had retained spacers, 1 underwent arthrodesis, and 2 patients died. Further surgical intervention after a failed prior two-stage exchange has poor outcomes. I&D has a high failure rate and many of the patients who are deemed candidates for a second two-stage exchange either do not undergo reimplantation for various reasons or fail after reimplantation. The management of PJI clearly remains imperfect, and there is a dire need for further innovations that may improve the care of these PJI patients.